This review provides an update on the diagnosis, risk stratification, and treatment of ventricular arrhythmias in cardiac sarcoidosis, focusing on evidence since the 2014 HRS consensus statement.
Answers are grounded in this paper and cite their sources.
Synthesizes post-2014 evidence on ventricular arrhythmias in cardiac sarcoidosis; leaves open need for prospective trials to guide practice.
The diagnosis of cardiac sarcoidosis (CS), especially in cases where there is limited or no extracardiac involvement, is challenging. Patients with CS are at increased risk of ventricular arrhythmias and sudden cardiac death. Several techniques for risk stratification for sudden cardiac death have been proposed in this population, including advanced cardiac imaging and electrophysiology study. Clinical ventricular arrhythmias in patients with CS may be treated with immunosuppressant therapy, antiarrhythmic drugs, catheter ablation, or implantable cardioverter-defibrillator placement. This article will provide an update on techniques for diagnosing CS, risk stratifying patients with CS for sudden cardiac death, and treating patients with CS with ventricular arrhythmias, focusing on evidence that has become available since publication of the 2014 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis.
No takes yet. Share an insight, caveat, or question.
Okada et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: